Literature DB >> 29084006

Review and update on postoperative opioid use after nasal and sinus surgery.

Sophia D Becker1, Daniel G Becker2.   

Abstract

PURPOSE OF REVIEW: We examine the current literature on pain management after sinus and nasal surgery. The goal after surgery is to provide effective pain management without having too many 'leftovers', as leftover medications are an important source of opioids that are fueling the current prescription narcotic epidemic in the United States. There are more than 250 000 sinus operations and 260 000 septoplasties performed annually, and surgeons commonly prescribe a narcotic pain medication for postoperative pain management. RECENT
FINDINGS: The literature suggests that an evidence-based approach may lead surgeons to prescribe significantly less narcotic pain medication for these procedures without affecting pain management.
SUMMARY: An evidence-based approach to pain management can result in unchanged pain control and a significant positive impact on the narcotic abuse epidemic.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29084006     DOI: 10.1097/MOO.0000000000000426

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  3 in total

1.  Opioid prescribing patterns within otolaryngology.

Authors:  Alexander W Murphey; Suqrat Munawar; Shaun A Nguyen; Ted A Meyer; Ashli K O'Rourke
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2019-05-09

2.  Opioid Use After Elective Otolaryngologic Surgery at a Teaching Institution.

Authors:  Basit A Jawad; Kevin K Lam; Colleen F Cecola; Edward D McCoul
Journal:  Ochsner J       Date:  2022

3.  Assessment of narcotic use in management of post-op pain after functional endoscopic sinus surgery.

Authors:  Kurren S Gill; Chandala Chitguppi; Michelle Haggerty; Tawfiq Khoury; Judd Fastenberg; Gurston Nyquist; Elina Toskala; Marc Rosen; Mindy Rabinowitz
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-01-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.